GlassScriptPhysician profile
Taslim Khattak
NPI 1679540298
$1,759.94
in general payments reported to CMS, 2019-2025
22 companies · $334 in 2025
The $334 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $771 · 2020: $118 · 2021: $166 · 2022: $150 · 2023: $120 · 2024: $100 · 2025: $334.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $554.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $554.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $401.30 | 2019-2021 | |
| Novo Nordisk INC | $310.30 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Madrigal Pharmaceuticals | $149.86 | 2025 | Rezdiffra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $129.74 | 2021-2025 | Jardiance |
| Intercept Pharmaceuticals, INC. | $124.96 | 2019 | |
| Boston Scientific Corporation | $106.81 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $88.07 | 2019-2025 | Breztri, Airsupra |
| Janssen Pharmaceuticals, INC | $78.70 | 2019 | |
| Medtronic Vascular, INC. | $63.68 | 2019 | |
| Merck Sharp & Dohme LLC | $35.02 | 2021 | |
| Pfizer INC. | $31.93 | 2019 | |
| Vyera Pharmaceuticals, LLC | $29.98 | 2019 | |
| Sun Pharmaceutical Industries INC. | $29.62 | 2022 | |
| Phathom Pharmaceuticals, INC. | $27.60 | 2024 | Voquezna |
| Lilly USA, LLC | $25.67 | 2022-2023 | Mounjaro |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $24.67 | 2022 | |
| Amgen INC. | $21.73 | 2025 | Repatha, Otezla |
| Hologic Sales and Service, LLC | $18.36 | 2020 | |
| Novartis Pharmaceuticals Corporation | $17.68 | 2023 | |
| Sanofi-Aventis U.S. LLC | $16.26 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $15.22 | 2022 | |
| Medicure Pharma INC. | $12.78 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Taslim Khattak listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.